{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "M. Osman Sheikh"}, {"accession": "MS:1000589", "name": "contact email", "value": "msheikh@amicusrx.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Amicus Therapeutics"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Dr. M. Osman Sheikh"}, {"accession": "MS:1000589", "name": "contact email", "value": "msheikh@amicusrx.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Amicus Therapeutics"}]}], "datasetFiles": [{"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/checksum.txt"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/GAAkif 10uM EndoH 10days Sites 6 and 7.xlsx"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/GAAkif+EndoH-10days.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/Lumizyme+EndoH-10days.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/LumizymeInput.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/rhGAA-kif+EndoH.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/rhGAA-kif.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/12-31-20 NeuAc Oxi.xlsx"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/LumiOxi+linker+aniline.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/Lumizyme AAOA Aniline %RA.xlsx"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/Lumizyme Input %RA.xlsx"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/Lumizyme_Input.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/NeuAcOxi_GAA.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/AOAA + Neuramin %RA.xlsx"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/Lum + Neuramin %RA.xlsx"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/Lumi+Neuraminidase_B.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/LumiAOAA+Neuraminidase_B.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/LumiOxi+Neuraminidase_B.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285/NeuOxi + Neuramin %RA.xlsx"}], "description": "Acid alpha-glucosidase (GAA) is a lysosomal glycogen-catabolizing enzyme, a deficiency in which leads to Pompe disease. Pompe disease can be treated with systemic recombinant human GAA (rhGAA) enzyme replacement therapy (ERT), but the current standard of care has poor uptake in skeletal muscles, limiting clinical efficacy. Further, it is unclear how the specific cellular processing steps of GAA post-delivery to lysosomes impact efficacy. GAA undergoes both proteolytic cleavage and glycan trimming within the endolysosomal pathway, yielding a more active enzyme for hydrolyzing its natural substrate glycogen. The relative contributions for each of these processing steps for increasing rhGAA glycogen hydrolytic activity are unclear. Here, we developed a tool kit of modified rhGAAs that allowed us to dissect the individual contributions of glycan trimming and proteolysis on maturation-associated increases in hydrolytic activity on glycogen. Chemical modifications of terminal sialic acids on N-glycans blocked sialidase activity in vitro and in cellulo, thereby preventing downstream glycan trimming without affecting proteolysis. This sialidase-resistant rhGAA displayed only partial activation following endolysosomal processing, as evidenced by lower catalytic efficiency on glycogen. We also generated enzymatically deglycosylated rhGAA that was shown to be partially activated despite not undergoing proteolytic processing. Taken together, these data suggest that an optimal rhGAA ERT would require both N-glycan and proteolytic processing to attain the most efficient enzyme kinetics for glycogen hydrolysis.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/05/PXD025285"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD025285"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD025285"}], "instruments": [{"accession": "MS:1002732", "name": "Orbitrap Fusion Lumos"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "glycogen storage disease, lysosomal glycoprotein, lysosomal storage disease, lysosome, enzyme processing, mannose-6-phosphate"}], "modifications": [{"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1002858", "name": "Dataset with its publication pending"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Endolysosomal processing of N-glycans on acid alpha-glucosidase is critical to attain the most active enzyme for hydrolyzing glycogen"}